600211 西藏药业
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,981,5386.23%3,134,3282,554,6092,138,5871,373,105
减:营业总成本1,988,7346.60%2,058,2971,813,0921,571,395951,130
    其中:营业成本172,4756.27%155,085146,694223,218194,965
               财务费用(69,078)46.41%(33,712)4,2916,750(13,543)
               资产减值损失(4,845)-2,552.49%(193,970)(276,664)(460,641)(722)
公允价值变动收益1,662-108.75%(210,533)(14,167)153,2542,549
投资收益7,481-50.47%40,4427,023(6,781)(1,600)
    其中:对联营企业和合营企业的投资收益(13,854)152.41%(4,271)(2,223)(9,687)(8,657)
营业利润1,043,832-10.05%899,093464,653256,800472,117
利润总额1,040,618-9.68%898,195463,392254,852470,315
减:所得税费用123,63730.13%87,95088,08341,82449,653
净利润916,981-13.25%810,245375,309213,027420,663
减:非控股权益(20,950)-462.03%9,3315,4694,0892,567
股东净利润937,931-10.78%800,914369,840208,938418,096

市场价值指针
每股收益 (元) *2.910-10.74%2.4801.4900.8401.690
每股派息 (元) *1.757-10.22%1.9390.7460.3380.510
每股净资产 (元) *11.785-3.05%13.49012.14710.60910.390
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容